SEC Form 4 · accession 0001209191-15-046930
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey T L Smith
Officer — Sr. VP Translational Medicine
Period of report
May 21, 2015
Accepted (ET)
May 26, 2015 · 7:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 21, 2015 | M | 54,616 | $0.055 | A | 54,616 | D | |
| Common StockF1 | May 21, 2015 | S | 54,616 | $38.9171 | D | 0 | D | |
| Common Stock | May 22, 2015 | M | 7,202 | $0.055 | A | 7,202 | D | |
| Common StockF2 | May 22, 2015 | S | 7,202 | $38.4653 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.055 | May 21, 2015 | M | 54,616 | D | — | Jul 18, 2015 | Common Stock | 54,616 | 7,202 | D |
| Stock Option (Right to Buy)F3 | $0.055 | May 22, 2015 | M | 7,202 | D | — | Jul 18, 2015 | Common Stock | 7,202 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $39.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
- F3The option is fully vested.